5AM Ventures

CAMP4 Therapeutics is a clinical-stage biotechnology company harnessing the power of RNA to address genetic diseases characterized by decreased protein expression. CAMP4’s RAP Platform® enables the mapping of regulatory RNA (regRNA) sequences that function as master regulators of gene expression and the design of programmable therapeutic ASO candidates targeting these regRNAs.

Ensoma is an in vivo hematopoietic stem cell (HSC) engineering company focused on creating a new kind of genomic medicine that treats diseases with a one-time treatment regimen by modifying cells of the hematopoietic system.

NodThera is a biotech company focused on developing therapies that target the NLRP3 inflammasome to treat chronic inflammatory diseases at their source.

Nouscom is a next-generation immunotherapy company developing engineered viral vectored vaccines for treatment of cancer, utilizing proprietary platforms to induce strong immune responses against tumors.

Karius is a company focused on architecture, offering various architectural services and projects.

TMRW® Life is a platform connecting hotel operations and guests, enhancing hotel management through mobile applications.

Rallybio is a clinical-stage biotech company committed to delivering groundbreaking therapies with the potential to truly transform the lives of millions of patients with devastating rare diseases.

Surrozen is pioneering therapies that harness the power of Wnt signaling to treat sight-threatening ophthalmic conditions. The company develops multi-target antibody therapeutics to improve and restore sight, focusing on addressing the underlying drivers of disease.

Homology Medicines, Inc. is a biotechnology company focused on developing genetic medicines to treat and cure rare genetic diseases through gene editing and gene therapy.

Crinetics is a global pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors.

ARCH Venture Partners invests at the concept stage, co-founding and building breakthrough life sciences and deep-science platforms directly with university researchers, acting as a company-builder partner to commercialize frontier biology. The firm concentrates its capital on breakthrough life sciences and deep science platforms with a stated mission to catalyze discoveries that prevent, detect, and cure disease.

Seed and early-stage investor that creates and invests in biotech startup companies, emphasizing company creation.

Early-stage drug-discovery company creator that originates companies in-house, incubates single ultra-orphan and rare-disease bets for years and millions, and commits to very long development timelines.

Creates and seeds about half its portfolio companies from in-house discovery labs (Ridgeline in Basel, Highline in New York), seeding them with tens of millions and re-running key experiments, importing big-pharma discipline into venture-backed biotech.

Healthcare-only platform spanning seed through IPO and beyond via public, private and credit/royalty arms; acts as a biotech IPO accelerator and validation, aiding NASDAQ/HKEX listings and confidential financings.